Advertisement
Advertisement
U.S. Markets close in 6 hrs 26 mins
Advertisement
Advertisement
Advertisement
Advertisement

Repligen Corporation (RGEN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
210.75-2.80 (-1.31%)
As of 09:33AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close213.55
Open203.33
Bid180.00 x 800
Ask244.68 x 1800
Day's Range210.73 - 212.02
52 Week Range137.21 - 306.98
Volume10,420
Avg. Volume531,123
Market Cap11.652B
Beta (5Y Monthly)0.95
PE Ratio (TTM)189.86
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement

    Signs 15-year Strategic Collaboration and Exclusive License AgreementWALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Through this agreement, Repligen will assume responsibility for the c

  • GlobeNewswire

    Repligen To Host Investor Day 2022

    WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Nasdaq MarketSite in New York City from 8:20 to 11:30 a.m. EDT. The event will feature presentations by several members of the company’s leadership team and will include Q&A discussion between the audience and Repligen pan

  • GlobeNewswire

    Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance

    Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year)Strong organic revenue growth of 29% and strong base business growth of 41% for the quarter Revenue guidance raised to $790 - $810 million for full year 2022 WALTHAM, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s

Advertisement
Advertisement